Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Technical Presentation (December 2025)
13 slides from Legend Biotech's technical presentation, Dec 6, 2025
Slide 1: A Phase 1 study of LUCAR-G39D in R/R B-cell non-Hodgkin lymphoma
A Phase 1 study of LUCAR-G39D: a novel anti- CD20/CD19 dual-CAR allogeneic γδ T cells in adults with relapsed/refractory B-cell non-Hodgkin lymphoma Jingwei Yu1, Linlin Cao2,3, Lanfang Li1, Jing Ming2,3, Zhengzi Qian1, Dandan Fan2,3, Lihua Qiu1, Xianming Liu1, Jiayi Han1, Jian Li4, Pu Wang4, Qing Da
Slide 2: Background
Background • Autologous CD19-targeted chimeric antigen receptor (CAR)-T cell therapies have demonstrated clinical benefit for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) • However, the efficacy of commercialized autologous CD19-targeted CAR-T cell therapies in patients
Slide 3: LUCAR-G39D: Allogenic CD19/CD20-targeted CAR-γδ T Cells
LUCAR-G39D: Allogenic CD19/CD20-targeted CAR-γδ T Cells Product Design • High-affinity anti-CD20 and anti-CD19 binders • Two co-stimulatory domains deliver diverse co-stimulatory signals • Two cytotoxicity domains mediate lysis of CD20+ and CD19+ tumor cells LUCAR-G39D Cytotoxicity Against CD20+ and
Slide 4: Study Design
Study Design LB2303 trial: a Single-arm, Open-label, Phase 1 Study in Subjects With R/R B-NHL Key eligibility criteria: • Age 18-75 years; ECOG PS 0-1 Lymphodepletion • large B-cell lymphoma(LBCL), follicular lymphoma (FL), Screening LUCAR-G39D Follow up cyclophosphamide + （28 days） infusion (Day 1
Slide 5: Subject Demographics and Baseline Characteristics
Subject Demographics and Baseline Characteristics DL1 DL2 DL3 DL4 DL5 Total n (%), unless otherwise stated （N=1） （N=4） （N=3） （N=6） （N=2） (N=16) Age, median (range) 61.0 58.0 (37,70) 55.0 (19,65) 54.0 (31,62) 56.5 (54,59) 55.5 (19,70) ≥65 years 0 1 (25.0) 1 (33.3) 0 0 2 (12.5) Sex, male 1 (100.0) 1 (
Slide 6: Safety Profile
Safety Profile n (%), DL1 DL2 DL3 DL4 DL5 Total unless otherwise stated (N=1） （N=4） （N=3） （N=6） （N=2） (N=16) • Median follow-up time was 6.1 months (range, 1.0-14.6 months) Any treatment- emergent adverse 1 (100.0) 4 (100.0) 3 (100.0) 6 (100.0) 2 (100.0) 16 (100.0) • Safety was manageable event (TEA
Slide 7: Pharmacokinetics and Immunogenicity
Pharmacokinetics and Immunogenicity CAR Transgene Copies (measured by qPCR) DL1 DL2 DL3 DL4 DL5 Total （N=1） （N=4） （N=3） （N=6） （N=2） (N=16) Subjects with PK n=1 n=3 n=2 n=6 n=2 n=14 expansion Cmax 1807.5 1331.0 8162.0 24765.5 149174.5 copies/μg DNA 668.0 (59, (59, 41859) (70, 16254) (68, 164768)
Slide 8: Efficacy
Efficacy n (%) DL1 DL2 DL3 DL4 DL5 Total Median follow-up time 6.1 months (range, 1.0-14.6 months) （N=1） （N=4） （N=3） （N=6） （N=2） (N=16) • Rate of CR was 37.5% 1 3 1 6 1 12 ORR • ORR (CR + PR) for 16 subjects was 75% (100.0) (75.0) (33.3) (100.0) (50.0) (75.0) • Median time to best response was 2.9 m
Slide 9: Clearance of Circulating Tumor DNA (ctDNA) Associates With Radiographic Response
Clearance of Circulating Tumor DNA (ctDNA) Associates With Radiographic Response LUCAR-G39D infusion led to robust tumor clearance by Day 30: • 11/13 (85%) subjects had reduced ctDNA and 6/13 (46%) achieved complete ctDNA negativity • ctDNA measurement indicated tumor reduction at an earlier timepoi
Slide 10: Case 1: LUCAR-G39D Leads to Rapid Tumor Clearance
Case 1 : LUCAR-G39D Leads to Rapid Tumor Clearance Baseline characteristics • 49-year-old man with FL Baseline fluorodeoxyglucose • IPI score 0 uptake • stage IV by tumor lesions Sites of • 2 prior lines of therapy PET-CT scan tumor Dose Level response • DL4 (400x106 CAR+T cells) Efficacy • PR at Da
Slide 11: Case 2: Durable Tumor Control in Absence of CAR-T Cells
Case 2: Durable Tumor Control in Absence of CAR-T Cells Baseline characteristics • 56-year-old man with DLBCL • IPI score 2 • Stage Ⅲ Baseline • Refractory to 1 line of therapy FDG uptake Sites of Dose Level PET-CT scan by tumor tumor lesions response • DL4 (400x106 CAR-T cells) Efficacy • SD at Day
Slide 12: Summary
Summary • LUCAR-G39D is an innovative dual-targeted (anti-CD20 and CD19) allogenic CAR-γδT cell therapy • In this phase 1 study of subjects with R/R B-NHL, it was well tolerated and manageable, with no DLTs, GVHD, or fatal events • Promising anti-tumor activity has been observed o 75.0% ORR o 37.5%
Slide 13: Acknowledgements
Acknowledgements • The authors would like to express their sincere gratitude to all subjects and their families for their participation and trust in this Phase I clinical trial (NCT06395870) • We extend our thanks to the investigators and research staff at all participating clinical sites for their
Legend Biotech — Technical Presentation (December 2025) on 6ix